You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • THU0212 Improved Remission Rates Acquired by Adding Adalimumab to Methotrexate and Intraarticular Glucocorticoid Cannot be Maintained after Withdrawal of Adalimumab. A 2-Year Investigator Initiated Randomised, Controlled Study on Early Rheumatoid Arthrit…

Article Text

Article menu

Download PDFPDF

Poster Presentation
Rheumatoid arthritis - anti-TNF therapy
THU0212 Improved Remission Rates Acquired by Adding Adalimumab to Methotrexate and Intraarticular Glucocorticoid Cannot be Maintained after Withdrawal of Adalimumab. A 2-Year Investigator Initiated Randomised, Controlled Study on Early Rheumatoid Arthritis
  1. K. Hørslev-Petersen1,
  2. M. L. Hetland2,
  3. P. Junker1,
  4. J. Pødenphant2,
  5. T. J. Ellingsen3,
  6. P. Ahlqvist1,
  7. H. M. Lindegaard1,
  8. A. Linauskas3,
  9. A. Schlemmer3,
  10. M. Y. Dam3,
  11. I. Hansen3,
  12. T. Lottenburger1,
  13. A. Jørgensen3,
  14. S. B. Krintel2,
  15. J. Raun1,
  16. C. G. Ammitzbøll3,
  17. J. S. Johansen2,
  18. M. Østergaard2,
  19. K. Stengaard-Pedersen3
  1. 1Rheumatology, University of Southern Denmark
  2. 2Rheumatology, University of Copenhagen
  3. 3Rheumatology, University of Aarhus, Denmark

Abstract

Background Recently we reported, that DAS28CRP<3,2 was achieved in more than 75% of early (< 6 months duration), treatment naïve rheumatoid arthritis (ERA) patients using methotrexate (MTX) + intraarticular (i.a.) triamcinolone (TRIAM) and in case of inadequate response after the 3rd month triple therapy with MTX, sulphasalazine (SZS) and hydroxychloroquine (HCQ)1. Addition of adalimumab (ADA) at baseline yielded even better clinical responses and remission rates after treatment for one year.

Objectives The purpose of the present investigation was to study whether the improved clinical response obtained by adding ADA to MTX + i.a. TRIAM injections can be maintained after withdrawal of ADA.

Methods Patients with ERA were randomized to receive i.a. TRIAM (40 mg/ml) in any swollen joint in combination with MTX (20 mg/wk) for two years and placebo-ADA (MTX+PLA) or MTX+ADA (40 mg eow) during the first year. Peroral glucocorticoid was not allowed. After 1 yr, ADA/PLA was withdrawn. If patients had swollen joints and DAS28(CRP)>3.2 during yr 2, SZS and HCQ were added, and if active disease persisted, ADA (40 mg eow) replaced SZS and HCQ in both treatment arms. Clinical response was assessed by DAS28(CRP), CDAI, SDAI and ACR/EULAR remission criteria. Analysis was by ITT with last observation carried forward. Medians (5%/95% percentiles) or percentage. Mann-Whitney or Pearson’s chi-square tests.

Results Baseline characteristics were similar in the MTX+PLA and MTX+ADA groups (DAS28(CRP) 5.6 (3.8-7.3) vs. 5.5 (3.8-7.8), NS). Table shows 1 and 2 years results. Serious adverse events were seen in 10 MTX+PLA patients (malignancy: 2, infections: 5, other: 2) and in 16 MTX+ADA patients (malignancy: 3, infections: 5, other: 8).

Figure

Conclusions Combined MTX and i.a. TRIAM provided excellent disease control at 2 years’ follow-up of ERA patients. The improved clinical responses observed during additional ADA administration could not be maintained after withdrawal of ADA. Radiographic data are needed to evaluate the overall effect of 1 yr of ADA as induction therapy in combination with MTX and i.a. TRIAM in ERA

References

  1. Hørslev-Petersen K et al. Ann Rheum Dis 2012:

Disclosure of Interest None Declared

https://doi.org/10.1136/annrheumdis-2013-eular.740

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.